绝经前肥胖女性的子宫内膜生物标志物:一个高危队列研究
该横断面研究前瞻性纳入体重指数≥30 kg/m²的绝经前女性97例和体重指数≤25 kg/m²的绝经前女性33例,评估血清代谢标志物及定时子宫内膜活检。肥胖女性组织学正常子宫内膜中孕激素受体、视黄醛脱氢酶2、胰岛素样生长因子1和生存素基因表达降低,而Lynch综合征合并肥胖女性胰岛素样生长因子1表达升高。
要点
- 肥胖绝经前女性子宫内膜孕激素受体、视黄醛脱氢酶2、胰岛素样生长因子1和生存素基因表达降低。
- 肥胖合并Lynch综合征女性子宫内膜胰岛素样生长因子1表达升高。
- 子宫内膜增殖无差异,免疫相关基因表达差异有限。
核心结论
- 无子宫内膜病理或遗传性癌症风险的绝经前女性中,肥胖者的子宫内膜生物标志物表达不反映局部高雌激素环境,而反映可能提示代偿状态的降低的癌症风险特征。
- 描述绝经前子宫内膜癌风险时,仅将高危状态归因于肥胖可能不够;需进一步研究评估个体化生物标志物谱以明确激素反应信号或免疫反应的差异。
- Lynch综合征患者中,子宫内膜生物标志物谱提示肥胖进一步增加癌症风险。
研究设计与样本
- 前瞻性横断面研究,纳入体重指数≥30 kg/m²的绝经前女性97例和体重指数≤25 kg/m²的绝经前女性33例。
- 评估血清代谢标志物,并进行定时子宫内膜活检用于病理评估、激素调节生物标志物分析和免疫反应基因表达分析。
- 获取内科和妇科病史;并在既往遗传性癌症风险(Lynch综合征)绝经前女性队列中比较不同体重指数组的子宫内膜基因表达标志物。
主要发现
- 肥胖女性组织学正常子宫内膜中孕激素受体基因表达降低(P=.0027),雌激素诱导基因视黄醛脱氢酶2(P=.008)、胰岛素样生长因子1(P=.016)和生存素(P=.042)表达降低,与无肥胖女性相比。
- 子宫内膜生物标志物胰岛素样生长因子1、生存素和孕激素受体在多变量线性回归模型中仍具统计学显著性。
- 肥胖合并Lynch综合征女性胰岛素样生长因子1表达升高(P=.017)。
- 子宫内膜增殖无差异,观察到的子宫内膜免疫差异有限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究评估个体化生物标志物谱以明确激素反应信号或免疫反应的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a well-known risk factor for endometrial cancer, but the mechanisms of obesity-related carcinogenesis are not well defined, particularly for premenopausal women. With the continuing obesity epidemic, increases in the incidence of endometrial cancer and a younger age of diagnosis are often attributed to a hyperestrogenic state created by hormone production in adipose tissue, but significant knowledge gaps remain. The balance of estrogen-responsive signals has not been defined in the endometrium of premenopausal women with obesity, where obesity may not create hyperestrogenism in the context of ovaries being the primary source of estrogen production. Obesity is associated with a state of low-grade, chronic inflammation that can promote tumorigenesis, and it is also known that hormonal changes alter the immune microenvironment of the endometrium. However, limited research has been conducted on endometrial immune-response changes in women who have an increased risk for cancer due to obesity. OBJECTIVE: Endometrial estrogen-regulated biomarkers, previously shown to be dysregulated in endometrial cancer, were evaluated in a cohort of premenopausal women to determine if obesity is associated with differences in the biomarker expression levels, which might reflect an altered risk of developing cancer. The expression of a multiplexed panel of immune-related genes was also evaluated for expression differences related to obesity. STUDY DESIGN: Premenopausal women with a body mass index of ≥30 kg/m2 (n=97) or a body mass index of ≤25 kg/m2 (n=33) were prospectively enrolled in this cross-sectional study, which included the assessment of serum metabolic markers and a timed endometrial biopsy for pathologic evaluation, hormone-regulated biomarker analysis, and immune response gene expression analysis. Medical and gynecologic histories were obtained. Endometrial gene expression markers were also compared across the body mass index groups in a previous cohort of premenopausal women with an inherited cancer risk (Lynch syndrome). RESULTS: In addition to known systemic metabolic differences, histologically normal endometria from women with obesity showed a decrease in gene expression of progesterone receptor (P=.0027) and the estrogen-induced genes retinaldehyde dehydrogenase 2 (P=.008), insulin-like growth factor 1 (P=.016), and survivin (P=.042) when compared with women without obesity. The endometrial biomarkers insulin-like growth factor 1, survivin, and progesterone receptor remained statistically significant in multivariate linear regression models. In contrast, women with obesity and Lynch syndrome had an increased expression of insulin-like growth factor 1 (P=.017). There were no differences in endometrial proliferation, and limited endometrial immune differences were observed. CONCLUSION: When comparing premenopausal women with and without obesity in the absence of endometrial pathology or an inherited cancer risk, the expression of the endometrial biomarkers does not reflect a local hyperestrogenic environment, but it instead reflects a decreased cancer risk profile that may be indicative of a compensated state. In describing premenopausal endometrial cancer risk, it may be insufficient to attribute a high-risk state to obesity alone; further studies are warranted to evaluate individualized biomarker profiles for differences in the hormone-responsive signals or immune response. In patients with Lynch syndrome, the endometrial biomarker profile suggests that obesity further increases the risk of developing cancer.
引用
- Dottino JA, Zhang Q, Loose DS, et al. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. Am J Obstet Gynecol. 2020. PMID: 32835719. doi:10.1016/j.ajog.2020.08.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。